Insights - Yesterday after market, Achillion (ACHN) released data and a strategic update, including interim data for C3G and PNH indications. The stock was down 20% leading up to … Continue Reading
Read nowInsights - During their R&D Day call last week, Affimed shared details on the clinical development plan for AFM13 in lymphomas. These future plans were a positive development after … Continue Reading
Read nowInsights - Bellus announced a $35M CDN raise this morning at $0.95 CDN. That is roughly equivalent to $0.71 USD. The Company is expected to net around $33M CDN, … Continue Reading
Read nowInsights - Oncosec finally announced an update from their early stage triple negative breast cancer trial. This data was presented last Thursday at the San Antonio Breast Conference. For … Continue Reading
Read nowInsights - There is a misconception that Bellus is lacking catalysts following their strong Phase 1 data released last week (read here). We don’t necessarily agree with the … Continue Reading
Read nowInsights - We are looking forward to December catalysts and watching two companies with near term readouts that we think the market is under appreciating. Both present … Continue Reading
Read nowInsights - Bellus had a call this morning (listen here) to discuss their Phase 1 data, released yesterday after market. As reported yesterday, at their anticipated therapeutic doses … Continue Reading
Read now
